We report the outcome of 24 patients with high-risk hematological malignancies or bone marrow failure (BMF) who received haploidentical bone marrow transplantation ( 
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative approach for many patients with hematological malignancies and certain non-malignant hematologic conditions. Although the majority of such patients will lack fully HLA-matched related donors, and many will also lack available HLA-matched unrelated donors, almost all will have available HLA-mismatched related donors. 1 However, HLA-mismatched HSCT is associated with increased graft failure, GvHD and a higher risk of treatment failure. 2 GvHD is predominantly mediated by alloreactive donor T cells which expand in vivo post-transplant. Non-selective T-cell depletion (nsTCD) of donor grafts is an efficient method for reducing alloreactivity and is very effective at preventing GvHD. While nsTCD has been combined with high CD34 + stem cell doses to achieve engraftment without severe GvHD in haploidentical HSCT, 3, 4 overall success of such strategies may be limited by delayed immune reconstitution, increased infectious complications, and higher relapse rates potentially associated with the loss of pathogen-and tumor-specific T cells. [5] [6] [7] Various experimental strategies to selectively deplete alloreactive T cells within the donor graft to prevent GvHD while preserving pathogen-and tumor-specific immunity have been developed with the aim of improving immune reconstitution after HLAmismatched HSCT. Most of these approaches utilize a common mechanistic platform of ex vivo donor T cell stimulation by recipient alloantigens and subsequent removal or destruction of alloreactive T cells, identified by expression of activation markers, proliferation or metabolic activity. [8] [9] [10] [11] [12] An alternative to selective allodepletion is induction of allospecific anergy 15 We previously reported early results of a clinical trial utilizing ex vivo induction of alloanergy in donor T cells within bone marrow (BM) grafts via CTLA4-Ig-mediated CSB. 16 This technique permitted large doses of HLA-mismatched donor T cells to be infused at the time of BMT with reliable engraftment and establishment of rapid full donor chimerism without excess severe aGvHD. We now report the immune reconstitution, infection and acute and chronic GvHD characteristics and long-term follow-up of a much larger cohort of patients with high-risk hematological malignancies or BMF who received HLA-mismatched BMT after ex vivo CSB to induce alloanergy.
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Methods

Patient and Donor Characteristics
Between March 1996 and March 2001, 24 patients entered Phase I studies of haploidentical BMT with ex vivo CSB using CTLA4-Ig (n=19) or anti-B7-1 and -B7-2 antibodies (n=5) on Dana-Farber Cancer Institute IRB-approved protocols. Patients (or their guardians) gave informed consent in accordance with the Declaration of Helsinki.
Follow up is reported through June 2008. Patients with high-risk hematological malignancies (subsequently also patients with congenital or acquired BMF other than Fanconi Anemia), were eligible as previously described. 16 Patient and donor details are summarized in 
Measurement of Residual Alloprecursor Frequency
Residual alloprecursor frequencies in alloanergized BM were determined in some patients by helper T lymphocyte precursor frequency assay (hTLPf), as previously described. 16 
Supportive Care
Patients received oral, non-absorbable antibiotics from admission until neutrophil engraftment, fluconazole for fungal prophylaxis and Pneumocystis Carinii prophylaxis with trimethoprim-sulfamethoxazole or pentamidine during conditioning and after D+30 or discharge. Patients received acyclovir prophylaxis at 100 mg/m 2 q12h if they were seropositive for HSV or at 250mg/m 2 q8h if the donor or recipient was CMV-seropositive.
Intravenous immunoglobulin (IVIg) was given weekly (400-500 mg/kg) until trough levels were self-sustaining at IgG >500mg/dL. Patients were monitored for CMV reactivation at weekly intervals by detection of CMV antigenemia. Patients who became CMV antigenemic received intravenous ganciclovir therapy.
Chimerism and Engraftment
Hematopoietic chimerism was determined on unfractionated blood or BM samples by fluorescence in situ hybridization in recipients with sex-mismatched donors or by polymerase-chain-reaction amplification of sequence specific primers or oligonucleotide probes for HLA class I and class II donor and recipient antigens. 
Definitions of acute and chronic GvHD and Performance Status
Definitions and statistical aspects
Data were analyzed using the Statistical Package for the Social Sciences (SPSS) (v.
10.0) software (SPSS Inc., Chicago, IL, USA). Associations between categorical variables was assessed using the χ-squared test. Overall survival was estimated using the method of Kaplan and Meier. 22 Transplant-related mortality (TRM), and relapse were calculated by the cumulative-incidence method using NCSS software (with relapse and TRM as the competing risks respectively). 23 To summarize the overall kinetics of immune 
Results
Engraftment and Chimerism
Cell doses infused are detailed in Table 1 
Toxicity
Twelve patients died of TRM. Two died of fungal infection, 2 from identified bacterial septicemia and one from a syndrome consistent with bacterial sepsis (organism unidentified). Four of these infection-related deaths occurred in patients with PD at BMT, whereas only one occurred in patients in CR. Five patients died from non-infectious toxicity; 2 from multi-organ failure (one of whom also had histological evidence of cerebral toxoplasmosis post-mortem), one from diffuse alveolar hemorrhage and one from hepatic veno-occlusive disease. One patient, for whom aGvHD was considered the primary cause of death, died with radiological evidence of fungal sinus infection while receiving immunosuppressive therapy. One patient was found dead at home, cause undetermined. Median time of TRM was D+53: three-quarters of toxic deaths occurred before D+100 and all before D+200 ( Table 2) . Cumulative incidence of TRM was 50%.
Recipient age (above median) was the only factor significantly associated with overall TRM. Median duration of hospitalization for the 13 patients who survived to discharge was 70 days (range 31-100).
GvHD
Eight of tract and skin involvement), on D+145 after discontinuing aGvHD prophylaxis on D+122, resolving after receiving slowly-tapering immunosuppression until D+355. The cumulative incidence of cGvHD (at 8 years) was only 8%.
Viral reactivation and infection
Of 11 at-risk patients (donor and/or recipient seropositive for CMV), 5 patients experienced a total of 7 episodes of CMV reactivation (45%, Table 2 ). UPNs 004, 021
and 024 reactivated on single occasions at D+64, D+32 and D+44 respectively. All was not seen until 6 months ( Figure 1F ). In 2 patients in which CD8 memory cell subsets were measured by dual-color CD45RA and CD62L expression, the majority of reconstituting memory CD8 cells had a CD45RA -CD62L -effector memory phenotype (data not shown). Endogenous immunoglobulin production recovered rapidly ( Figure   1G ) and IVIg replacement was discontinued at a median of 4 months post-BMT.
To evaluate factors affecting the kinetics of T cell reconstitution, AUC analysis was performed ( However, although no significant difference was seen in CD4 + T cell AUC at 3, 6 or 12 months, there was a trend towards greater CD8 + T cell AUC at 4 months and 6 months and significantly greater CD8 + T cell AUC at 12 months in those that reactivated CMV compared to those who did not.
The more rapid expansion of CD8 + T cells in the 3 evaluated patients who reactivated CMV (UPNs 009, 021 and 024) compared to the 5 who did not is shown in Figure 2A . A rapid and sustained expansion of EBV-specific pentamer + CD8 + T cells was also observed in all 4 evaluated patients with HLA A2 + EBV-seropositive donors ( Figure 2E ).
Outcome
Actuarial event-free survival (EFS) was 33% at 10 years for the whole patient cohort.
EFS was significantly higher in patients aged <18 years than in those aged >18 years.
The difference in EFS in pediatric and adult patients was due to increased early TRM in adult patients ( 
Discussion
In these two Phase 1 clinical studies, myeloablative haploidentical BMT containing large numbers of alloanergized donor T cells resulted in acceptable engraftment and less severe aGVHD than historical reports using unmanipulated haploidentical BM.
Moreover, alloanergized BMT was associated with rapid T cell reconstitution, in vivo expansion of pathogen-specific CD8 + T cells and early recovery of immunoglobulin production. While substantial early TRM was observed in these very high risk patients, no TRM was related to viral infection, and long-term disease-free survival uncomplicated by cGVHD was seen in one third of patients.
Alloanergization did not appear to impair immune reconstitution. The median ALC D+30 in our study (0.42 x 10 9 /L), evaluated for all patients who survived to engraftment, was similar to that reported after conventional unmanipulated BMT from HLA-matched sibling donors (0.49 x 10 9 /L). 24 Both ALC and CD4 + T cell counts rose rapidly by 3 months. The presence of CD4 + cells with a predominantly memory phenotype during the initial period post-BMT, when rapid recovery of T cell counts occurred, was consistent with peripheral expansion of mature donor T cells contained in the BM graft. In contrast naïve CD4 + T cells were not detectable in the periphery until 6 months post-BMT. Although the favorable prognostic value of early ALC recovery reported after adult and pediatric matched sibling HSCT 25, 26 has not been established after haploidentical BMT, and cannot be inferred from our limited data, the observed recovery of ALC suggests donor lymphocytes maintained their capacity to expand in vivo after alloanergization. Indeed, rapid reconstitution of T cell subsets occurred in patients evaluable for immune reconstitution (all of whom were < 18 years of age). The median time to achieve a CD4 + T cell count of 300/µL was 3 months, faster than the 8 months observed after haploidentical CD34-selected BMT in children reported by Eyrich et al, 27 and comparable to the 4 months observed after CD34-selected HSCT followed by infusion of 10 5 selectively allodepleted donor T cells/kg reported by Amrolia et al. 28 In contrast to a recent study of immune reconstitution after haploidentical HSCT, 29 our AUC analysis demonstrated that CD4 + and CD8 + T cell recovery was not adversely affected by the presence of aGvHD, probably reflecting the modest dose and duration of corticosteroid treatment in most patients who developed aGvHD. Conversely, the In common with other reports of graft manipulation techniques to selectively reduce alloreactivity, we also lack data demonstrating antigen-specific CD4 + responses.
However, we have recently demonstrated that CMV-specific CD4 + T cells are retained after alloanergization in vitro. If such cells are also retained after alloanergized BMT, they might be capable of providing pathogen-specific memory responses needed to maintain CMV immunity in vivo post-BMT. 33 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
The optimum dose of alloanergized T cells able to improve pathogen-specific immune reconstitution without significant GvHD remains to be determined, and may be significantly lower than the doses in this study. Although administration of alloanergized donor T cells was associated with aGVHD in 43% of patients, three-quarters of those with aGvHD responded to brief courses of corticosteroids. Steroid-refractory aGvHD only occurred in 2 patients (9%), despite a median T cell dose 2 logs greater than the dose (8-20 x 10 4 /kg) at which 30% of children undergoing nsTCD haploidentical HSCT were observed to develop steroid-refractory GvHD and 3 logs above a published threshold dose below which severe aGvHD was reliably prevented in the haploidentical setting.
34,35
AGvHD did not occur more often in those patients receiving CD3 + , CD4 + or CD8 + T cell doses above median levels, and although alloreactive precursor frequency data was available on a relatively small proportion of patients, we also did not see an association between residual in vitro CD4 + alloresponses and aGvHD occurrence. A potential explanation for this observation might be that residual alloresponses after alloanergization are mediated in vivo by CD28 -donor T cells (which are predominantly CD8 + ), γδ T cells, or successfully alloanergized CD4 + donor T cells that had their anergic state temporarily reversed by high levels of cytokines in vivo. 36, 37 We also observed an unusual distribution of organ involvement in patients with aGvHD, predominantly limited to the GI tract, suggesting that donor T cells with residual alloreactivity preferentially targeted the gut. Murine GI-specific alloresponses mediated by CD8 + cells are not abrogated by CD28-blockade; such cells may receive CD28-independent positive costimulatory signals via CD134. 38, 39 Alternatively, GI tract aGVHD may have been disproportionately driven by non-allospecific mechanisms.
Our strategy resulted in a low cumulative incidence of cGvHD (8%) comparable to nsTCD haploidentical HSCT, 4, 40 and surviving patients were therefore free of cGvHDassociated morbidity and immunosuppression. In contrast, recent studies of T-replete G-CSF-stimulated haploidentical BMT have reported up to 70% cGvHD (and nearly 50% extensive cGvHD) in both adults and children. 41 Recent series of nsTCD haploidentical HSCT have reported significant rates of late TRM in both children and adults, predominantly from delayed T cell immune reconstitution and viral infections, resulting in overall TRM of 40-60%. 4, 40, 42, 43 In contrast we saw no significant morbidity or mortality related to viral infection and no TRM after 6 months post-BMT. While the incidence of CMV reactivation in our study was lower than that in recent reports of nsTCD haploidentical HSCT, many such studies used detection techniques with greater sensitivity. 42, [44] [45] [46] However, the CMV reactivation observed was associated with high rates of fatal CMV disease in many such studies; up to 60% of TRM was related to CMV infection and up to 16% of all patients transplanted dying from human herpes virus-related infections, the vast majority from CMV. 4, 43 In our studies, there was no CMV-related TRM. Furthermore, we saw no mortality from adenovirus. In contrast, adenovirus-related deaths occurred in 10-18% of children with acute leukemia receiving nsTCD haploidentical HSCT (either by addition of alemtuzumab or CD34-selection of donor grafts). 40, 47 We are encouraged that alloanergized BMT was associated with low incidences of steroid-refractory aGvHD, cGvHD and viral infection, and with rapid T cell reconstitution, a key area of therapeutic weakness in many other current strategies for haploidentical HSCT. The adoptive transfer of non-alloreactive donor T cell doses as low as 10 5 /kg has also been associated with improved viral-specific immune reconstitution after haploidentical CD34-selected HSCT, although relapse remained a significant problem, occurring in 7 of 16 patients. 28 While early TRM and small patient numbers preclude any conclusions regarding long-term disease control, cumulative incidence of relapse/progression in our study was low at 17% with long follow-up.
The major limitation to our strategy, however, was significant early TRM, particularly in adult patients. While the engraftment rate was comparable to alternate strategies of haploidentical HSCT, 4, 40, [48] [49] [50] For personal use only. on October 3, 2017. by guest
